Skip to Main Content

Author Details

Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
2002
42
17
PMIDPaper TitleJournal TitlePublished Year
36379463Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations.Z Gastroenterol2023
37562657Deep Learning-Enabled Diagnosis of Liver Adenocarcinoma.Gastroenterology2023
37586177Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Lung Cancer2023
37327584Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD).Transl Oncol2023
36635225First proficiency testing for NGS-based and combined NGS- and FISH-based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma.J Pathol Clin Res2023
33468537Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.Gut2022
35430765Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary.Genes Chromosomes Cancer2022
35681079Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).NPJ Precis Oncol2022
35871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022
34331337Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.Genes Chromosomes Cancer2022
33441414Accurate and efficient detection of gene fusions from RNA sequencing data.Genome Res2021
33686791KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.Genes Chromosomes Cancer2021
33667718Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.Lung Cancer2021
34521064Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary.Eur J Cancer2021
34487971The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.ESMO Open2021
34605937Erratum zu: Varianteninterpretation in dermolekularen Pathologie und Onkologie.Pathologe2021
33938987[Variant interpretation in molecular pathology and oncology : An introduction].Pathologe2021
34112699Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.Cancer Discov2021
31558800Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains.Oncogene2020
31970771Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.Int J Cancer2020
31776646Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1.Virchows Arch2020
32280037High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.Urol Oncol2020
32212351Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.Genes Chromosomes Cancer2020
30446996Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.Int J Cancer2019
30238975Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.Int J Cancer2019
30230086Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.Genes Chromosomes Cancer2019
31491926RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.Cancers (Basel)2019
31349062Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.J Thorac Oncol2019
31008532Variant classification in precision oncology.Int J Cancer2019
30963573Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.Int J Cancer2019
30901310<i>RSPO2</i> gene rearrangement: a powerful driver of β-catenin activation in liver tumours.Gut2019
30653256Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.Int J Cancer2019
30669647Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.Cancers (Basel)2019
30505715Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.Transl Lung Cancer Res2018
35135162Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.JCO Precis Oncol2018
27782876Interplay of demographic variables, birth experience, and initial reactions in the prediction of symptoms of posttraumatic stress one year after giving birth.Eur J Psychotraumatol2016
25405317Protumorigenic role of Timeless in hepatocellular carcinoma.Int J Oncol2015
24285179EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.Hepatology2014
22689435Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.Hepatology2012
23102701Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes.Mol Cell2012
21372220Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.Clin Cancer Res2011
12436360[About the addiction to using the telephone or a structural approach in the crisis intervention for a better work with long-term users].Psychiatr Prax2002
  • 1 - 42 of 42

Recommended Authors

Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 3
Daniel Vod??k
Institute for Cancer Research, Oslo University Hospital
Career Start Year 2014
Number of shared co-authors 4
Hiroko Tanaka
Tokyo Medical and Dental University
Career Start Year 2012
Number of shared co-authors 4
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 1
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 2
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 0
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Ignaty Leshchiner
Broad Institute of Massachusetts Institute of Technology and Harvard
Career Start Year 2008
Number of shared co-authors 0
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 1
Francine B de Abreu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 0
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 1
Sadakatsu Ikeda
Tokyo Medical and Dental University Hospital
Career Start Year 2006
Number of shared co-authors 0
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 4
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 11
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 6
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 4
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 5
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 0
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 0
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 0
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Dirce Maria Carraro
AC Camargo Cancer Center
Career Start Year 1998
Number of shared co-authors 0
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 0
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 6
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 0
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 4
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 0

Collaborators

Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 35
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 34
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 26
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 23
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 22
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 20
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 20
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 16
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 15
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 7
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 7
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 7
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 6
Huriye Seker-Cin
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 5
Barbara Hutter
National Center for Tumor Diseases (NCT) Heidelberg
Co-authored papers 5
Ivo Buchhalter
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Co-authored papers 5
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers 4
Simon Kreutzfeldt
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 4
Andreas von Deimling
Co-authored papers 3
Hannah Goldschmid
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 3
Christof von Kalle
Berlin Institute of Health at Charite-Universitatsmedizin Berlin
Co-authored papers 3
Stephanie Roessler
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 3
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 3
Markus Ball
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 3
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 3
Susanne Beck
Vrije Universiteit Brussel (VUB)
Co-authored papers 2
Stephan Wolf
Co-authored papers 2
Esther Herpel
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 2
Harmen J Bussemaker
Co-authored papers 1
Dieter Weichenhan
German Cancer Research Center (DKFZ)
Co-authored papers 1
Release 1.2